Compare Quest Diagnostics Inc (DGX) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Occidental Petroleum Corporation — how do they compare? Quest Diagnostics Inc trades at $204.65 (market cap $22.80B), while Occidental Petroleum Corporation trades at $53.99 (market cap $54.28B). The key difference: Occidental Petroleum Corporation is far larger — about 2.4× Quest Diagnostics Inc's market cap, and Occidental Petroleum Corporation pays the higher dividend (1.91%). Which is the better fit depends on your goals.
| DGX | OXY | |
|---|---|---|
Market Cap | $22.80B | $54.28B |
Sector | Health | Energy |
52-Week High | $216.02 | $66.24 |
52-Week Low | $166.42 | $38.92 |
Enterprise Value | $28.82B | $75.36B |
Dividend Yield | 1.67% | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Occidental Petroleum (OXY) trades at $54.81, up 3.63% with bullish technical signals and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust profitability with 22.42% net income margin and 14.04% ROE, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Analyst consensus is positive with 50% buy ratings and $66.14 price target, while recent news highlights operational improvements and geopolitical tailwinds from higher oil prices.
OXY presents a compelling investment case with earnings outperformance, debt reduction progress, and favorable oil price environment, but faces risks from commodity volatility and execution challenges in carbon capture initiatives. The stock's current valuation at 74x P/E requires sustained earnings growth to justify further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
